Comprehensive Monograph on Teniposide (VM-26, Vumon)

Part 1: Foundational Profile and Pharmacology

1.1. Overview and Identification

Teniposide is a semi-synthetic derivative of podophyllotoxin, a naturally occurring lignan. It is classified as an antineoplastic agent and functions as a specific inhibitor of DNA topoisomerase II.[1] In the United States, its primary and sole approved indication is for induction therapy in combination with other anticancer agents for refractory childhood acute lymphoblastic leukemia (ALL).[4] Its application is broader in Europe, where it is also approved for the treatment of Hodgkin's lymphoma, various primary brain tumors, neuroblastoma, and other pediatric malignancies.[7]

The compound is identified by several names and codes, including its chemical name, the code name VM-26, and the trade names Vumon® and Vehem®.[6] A comprehensive summary of its identifiers and chemical properties is provided in Table 1.

Table 1: Drug Identification and Chemical Properties of Teniposide

Property	Value	Source(s)
DrugBank ID	DB00444	4
Type	Small Molecule	4
CAS Number	29767-20-2	6
IUPAC Name	(5S,5aR,8aR,9R)-5-dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-benzofuro[6,5-f]benzodioxol-8-one	3
Molecular Formula	$C_{32}H_{32}O_{13}S$	6
Molecular Weight	656.65 - 656.7 g/mol	6
InChIKey	NRUKOCRGYNPUPR-QBPJDGROSA-N	6
Canonical SMILES	COC1=CC(=CC(=C1O)OC)[C@H]2[C@@H]3C@HO[C@H]6O
Synonyms/Codes	VM-26, Vumon, Vehem, NSC 122819, EPT, PTG

1.2. Chemical Synthesis and Physicochemical Properties

Teniposide's development originates from efforts to modify podophyllotoxin, a cytotoxic lignan extracted from the rhizome of the American mandrake plant, Podophyllum peltatum, to create derivatives with an improved therapeutic index. It is a glycoside of podophyllotoxin, specifically identified as 4'-demethylepipodophyllotoxin 9-(4,6-O-(R)-2-thenylidene-beta-D-glucopyranoside). The semi-synthetic manufacturing process involves a condensation reaction between thiophene-2-aldehyde and 4'-demethylepipodophyllotoxin.

Physically, Teniposide is a white to off-white crystalline solid. It has a melting point in the range of 242–246 °C. As a lipophilic compound, it is practically insoluble in water, with an estimated solubility of only 5.9 mg/L at 25 °C, and is also insoluble in ether. Conversely, it is very soluble in organic solvents such as acetone and dimethylformamide. For long-term stability, the powdered form of the drug should be stored at -20°C.

1.3. Mechanism of Action

The primary antineoplastic mechanism of Teniposide is the inhibition of DNA topoisomerase II alpha, a critical enzyme involved in managing DNA topology during replication, transcription, and repair. Unlike classic cytotoxic agents such as anthracyclines, Teniposide does not intercalate into the DNA helix or bind strongly to DNA. Instead, its action is more specific: it binds to the topoisomerase II enzyme after the enzyme has created a transient double-strand break in the DNA. This forms a stable ternary complex involving Teniposide, the enzyme, and the cleaved DNA.

By stabilizing this "cleavable complex," Teniposide prevents the topoisomerase II enzyme from completing its catalytic cycle, specifically inhibiting the re-ligation of the broken DNA strands. The persistence and accumulation of these stabilized complexes result in dose-dependent single- and double-stranded DNA breaks, as well as DNA-protein cross-links. The cellular DNA damage response mechanisms are overwhelmed by these lesions, ultimately triggering the apoptotic cell death pathway.

Teniposide's cytotoxicity is cell-cycle specific. It exerts its maximum effect during the late S (DNA synthesis) and early G2 (pre-mitotic) phases of the cell cycle, thereby arresting cells and preventing their entry into mitosis. This phase specificity is a crucial consideration in the design of clinical chemotherapy schedules to maximize its efficacy against proliferating cancer cells. In addition to its primary mechanism, some evidence suggests a secondary effect involving the inhibition of oxidative phosphorylation, indicated by observed mitochondrial abnormalities and reduced NADH-linked respiration in treated cells.

1.4. Comparative Pharmacology: Teniposide vs. Etoposide

Teniposide is structurally and mechanistically similar to etoposide; both are epipodophyllotoxin derivatives developed to improve upon the toxicity profile of the parent compound, podophyllotoxin. The sole structural distinction is the substitution on the glucopyranoside ring: Teniposide possesses a thienyl group, whereas etoposide has a methyl group. This seemingly minor chemical modification leads to significant differences in their pharmacological profiles.

In vitro, Teniposide is a more potent cytotoxic agent than etoposide, demonstrating approximately 3- to 10-fold greater activity in producing DNA damage and killing cancer cells. A key factor contributing to this superior potency is its enhanced cellular uptake. Teniposide is more readily transported into cells, leading to higher intracellular drug concentrations and, consequently, a greater capacity for cytotoxicity, even though its direct inhibitory effect on the topoisomerase II enzyme is not substantially greater than that of etoposide.

However, this superior in vitro potency does not directly translate to broader clinical superiority, a phenomenon that can be described as a "potency-bioavailability paradox." The clinical utility of Teniposide is significantly modulated by its unfavorable pharmacokinetic properties in vivo. It exhibits extremely high plasma protein binding, with over 99% of the drug bound to proteins like albumin. This extensive binding drastically reduces the concentration of free, pharmacologically active drug available to diffuse into tumor tissues. This effectively counteracts its higher intrinsic potency at the cellular level. In contrast, etoposide is less extensively protein-bound, resulting in a higher fraction of unbound drug. Furthermore, the early development of an oral formulation for etoposide was perceived as a major clinical advantage, contributing to its more widespread investigation and adoption. This divergence illustrates a critical principle in drug development: favorable pharmacokinetics and bioavailability are as crucial as molecular potency for achieving clinical success.

1.5. Pharmacokinetics: Absorption, Distribution, Metabolism, and Excretion (ADME)

Absorption: Teniposide is administered exclusively via the intravenous route, resulting in 100% bioavailability.

Distribution: As a highly lipophilic compound, Teniposide distributes into tissues, but its distribution is heavily influenced by its extensive plasma protein binding (>99%). The steady-state volume of distribution is relatively small, reported as 3 to 11 L/m² in children and 8 to 44 L/m² in adults. In patients with hypoalbuminemia, the reduced protein binding can lead to an increased volume of distribution and a higher fraction of free drug, potentially increasing the risk of toxicity. Penetration across the blood-brain barrier is generally limited, although higher cerebrospinal fluid (CSF) concentrations have been observed in patients with existing brain tumors.

Metabolism: The liver is the primary site of Teniposide metabolism. The metabolic pathways include conversion to its active catechol metabolite, a reaction mediated in part by the cytochrome P450 enzyme CYP3A4, though this process occurs more slowly for Teniposide than for etoposide. Teniposide is also a known substrate of the P-glycoprotein (P-gp) efflux transporter, which can influence its distribution and contribute to drug resistance.

Excretion: Following intravenous infusion, plasma concentrations of Teniposide decline in a biexponential manner. It has a longer terminal elimination half-life of approximately 5 hours compared to etoposide. Elimination occurs through both renal and fecal routes. Reflecting its more extensive metabolism, only 10% to 20% of a dose is excreted unchanged in the urine, a significantly lower proportion than the 30% to 70% observed with etoposide.

Part 2: Clinical Application and Patient Management

2.1. Approved and Off-Label Indications

The approved clinical uses of Teniposide vary significantly by regulatory region.

• United States: The U.S. Food and Drug Administration (FDA) has approved Teniposide for a single, specific indication: as a component of combination induction therapy for refractory childhood acute lymphoblastic leukemia (ALL).
• Europe: Regulatory approval in Europe encompasses a wider spectrum of pediatric malignancies. In addition to acute leukaemia, indications include Hodgkin's lymphoma, generalized malignant lymphoma, reticulocyte sarcoma, primary brain tumours (such as glioblastoma, ependymoma, and astrocytoma), bladder cancer, and neuroblastoma.
• Canada: Health Canada has approved its use for neuroblastoma, non-Hodgkin's lymphoma, and acute lymphocytic leukemia.
• Off-Label and Investigational Uses: Teniposide has been clinically evaluated and used off-label for several other cancers, including adult non-Hodgkin's lymphoma, small cell lung cancer, breast cancer, and oral squamous cell carcinoma.

2.2. Dosing Regimens and Administration

Formulation: Teniposide is supplied as a sterile, nonpyrogenic solution for injection in 50 mg/5 mL (10 mg/mL) ampules. The formulation is a nonaqueous medium containing several excipients, notably Cremophor® EL (polyoxyl 35 castor oil), which is used to solubilize the lipophilic drug, along with N,N-dimethylacetamide, benzyl alcohol, and dehydrated alcohol.

Preparation and Dilution: Prior to administration, Teniposide must be diluted with either 5% Dextrose Injection, USP, or 0.9% Sodium Chloride Injection, USP. The final concentration for infusion should be 0.1 mg/mL, 0.2 mg/mL, 0.4 mg/mL, or 1.0 mg/mL. Diluted solutions at concentrations of 0.1, 0.2, and 0.4 mg/mL are stable at room temperature for up to 24 hours. However, to minimize the risk of precipitation, the 1.0 mg/mL solution should be administered within 4 hours of preparation. Refrigeration of diluted solutions is not recommended.

Administration: Teniposide must be administered as a slow intravenous infusion over a period of at least 30 to 60 minutes. Rapid intravenous injection is strictly contraindicated due to the risk of severe hypotension, an effect potentially mediated by the Cremophor® EL excipient.

Representative Dosing Regimens:

• Refractory Childhood ALL:
• In combination with cytarabine: Teniposide 165 mg/m² and cytarabine 300 mg/m² administered intravenously, twice weekly for 8 to 9 doses.
• In combination with vincristine/prednisone: Teniposide 250 mg/m² and vincristine 1.5 mg/m² intravenously, weekly for 4 to 8 weeks, along with oral prednisone.
• Non-Hodgkin's Lymphoma (Off-label): Dosing schedules have included 30 mg/m²/day for 10 days or 50 to 100 mg/m² once weekly.

2.3. Clinical Efficacy and Landmark Studies

Clinical studies have established the efficacy of Teniposide, particularly in heavily pretreated and refractory pediatric populations.

A pivotal study conducted at St. Jude Children's Research Hospital (SJCRH) enrolled nine children with ALL who had failed initial induction therapy with a cytarabine-based regimen. Treatment with a combination of Teniposide and cytarabine induced complete remission in three of these patients. The durability of these responses was notable, with remission durations of 30 weeks, 59 weeks, and, in one case, 13 years, underscoring its potential for long-term disease control in a highly refractory setting.

Another study at SJCRH evaluated Teniposide in 16 children with ALL that was refractory to standard vincristine/prednisone-containing regimens. The addition of Teniposide to vincristine and prednisone demonstrated clinical activity in this challenging patient group.

In the context of non-Hodgkin's lymphoma, a randomized trial compared a standard regimen (ACVP: doxorubicin, cyclophosphamide, vincristine, prednisolone) with a Teniposide-containing regimen (ACTP) and a combination of both (ACTVP). The results showed that the Teniposide regimen (ACTP) produced complete remission rates (46%) and survival outcomes comparable to the vincristine regimen (ACVP, 44% CR). Importantly, ACTP was not associated with the neurotoxicity seen with vincristine. However, the study also found that combining Teniposide and vincristine (ACTVP) did not improve efficacy but significantly increased both neurotoxicity and myelosuppression, providing important guidance on its optimal use in combination therapy.

2.4. Management in Special Populations

The use of Teniposide requires careful consideration and dose adjustments in specific patient populations.

• Pediatrics: Teniposide's primary indication is for pediatric cancers. Clinical studies have not identified unique pediatric-specific problems that would limit its use beyond the well-established toxicity profile applicable to all patients.
• Geriatrics: Data on geriatric use are limited. However, elderly patients are generally considered more susceptible to chemotherapy-related adverse effects, particularly hypotension. A report of sudden death in an elderly patient, attributed to arrhythmia and hypotension, highlights the need for caution in this population.
• Down Syndrome: Patients with Down syndrome exhibit increased sensitivity to the myelosuppressive effects of many chemotherapeutic agents, including Teniposide. For these patients, it is recommended that the initial dose be reduced by 50% to mitigate the risk of severe hematologic toxicity.
• Renal and Hepatic Impairment: Teniposide is contraindicated in patients with severe renal or hepatic dysfunction. In patients with mild-to-moderate impairment, the drug should be used with caution, as slower clearance may lead to increased drug exposure and toxicity. Close monitoring of blood counts, as well as renal and hepatic function, is mandatory before and during therapy.
• Hypoalbuminemia: Due to its high degree of plasma protein binding, patients with low serum albumin levels may have a higher concentration of unbound, active Teniposide. This can increase the risk of toxicity, and such patients should be monitored closely.

Part 3: Safety, Toxicology, and Risk Management

3.1. Comprehensive Adverse Effects Profile

The clinical use of Teniposide is associated with a significant and predictable toxicity profile, with myelosuppression being the most critical dose-limiting factor. A summary of key adverse reactions is provided in Table 2.

Table 2: Summary of Key Adverse Reactions to Teniposide

System Organ Class	Adverse Reaction	Frequency / Notes	Source(s)
Hematologic	Myelosuppression (Dose-Limiting)	Very Common
	Neutropenia	95%; Nadir at 7-14 days, recovery by 14-21 days
	Thrombocytopenia	80-85%; Nadir at 7-14 days, recovery by 14-21 days
	Anemia	88%
	Leukopenia	65-89%
Immune System	Hypersensitivity Reaction	1-5% (Common); Can be life-threatening (anaphylaxis-like)
		Symptoms: chills, fever, tachycardia, bronchospasm, dyspnea, hypotension/hypertension, rash, flushing
Gastrointestinal	Mucositis / Stomatitis	76% (Very Common)
	Nausea and Vomiting	10-30% (Common)
	Diarrhea	Common
	Anorexia	Common
Skin and Subcutaneous Tissue	Alopecia	9% (Common); Reversible
	Rash	Common
Cardiovascular	Hypotension	2% (Uncommon); Associated with rapid infusion
General Disorders and Administration Site	Extravasation Hazard	Irritant; can cause tissue necrosis
	Phlebitis	Possible at IV site
Nervous System	Peripheral Neurotoxicity	Reported
	Acute CNS Depression	Reported, especially with high doses
Neoplasms (Long-term)	Secondary Leukemia (t-ANLL)	5-12%; Risk is schedule- and dose-dependent

3.2. Black Box Warnings and Contraindications

The FDA label for Teniposide carries a black box warning highlighting its significant risks. The warning stipulates that:

• Teniposide is a potent cytotoxic drug and should only be administered under the supervision of a qualified physician experienced in the use of cancer chemotherapeutic agents.
• Appropriate management of therapy and its complications is possible only when adequate treatment facilities are readily available.
• Severe myelosuppression, with resulting infection or bleeding, may occur.
• Hypersensitivity reactions, including anaphylaxis-like symptoms, may occur and can be life-threatening.

Contraindications for the use of Teniposide include:

• Known hypersensitivity to Teniposide or any of its excipients, particularly Cremophor® EL (polyoxyethylated castor oil).
• Severe pre-existing bone marrow suppression.
• Severe renal or hepatic impairment.
• Concurrent administration of live virus vaccines (e.g., yellow fever, measles, mumps, rubella) due to the risk of vaccine-induced disseminated disease in an immunosuppressed patient.

3.3. Long-Term Toxicities: Carcinogenicity and Genotoxicity

The most serious long-term consequence of Teniposide therapy is the risk of developing a secondary malignancy, most commonly therapy-related acute nonlymphocytic leukemia (ANLL) or myelodysplastic syndrome (MDS). This risk exemplifies the "double-edged sword" nature of genotoxic chemotherapy. The very mechanism that confers its therapeutic efficacy—the induction of DNA double-strand breaks in cancer cells—is also responsible for its carcinogenic potential. Sublethal DNA damage inflicted upon healthy hematopoietic stem and progenitor cells can lead to mutations and chromosomal aberrations. Over time, these genetic insults can drive clonal expansion and malignant transformation.

The risk is not uniform and is highly dependent on the treatment schedule and cumulative dose. Studies have shown that prolonged, low-dose maintenance schedules (e.g., weekly or twice-weekly administration) are associated with a significantly higher risk of secondary leukemia, with a relative risk approximately 12 times greater than that observed in patients treated with other regimens. In contrast, short, intensive courses used for remission induction and consolidation have not been associated with the same elevated risk. This observation underscores that the frequency and chronicity of DNA insults to the stem cell pool are critical determinants of leukemogenesis.

Teniposide's carcinogenic potential is supported by its genotoxicity profile. It is mutagenic in the Ames test and is a potent clastogen, inducing DNA damage and chromosomal aberrations in a variety of in vitro and in vivo mammalian cell assays.

3.4. Use in Pregnancy and Lactation

Pregnancy: Teniposide is classified as FDA Pregnancy Category D, indicating positive evidence of human fetal risk. The drug should not be used during pregnancy unless the potential benefit to the mother justifies the potential risk to the fetus. Animal studies have demonstrated that Teniposide is both teratogenic and embryotoxic, causing major fetal anomalies including spinal and rib defects and deformed extremities. Women of childbearing potential must be counseled on the risks and advised to use effective contraception throughout the treatment period.

Lactation: It is unknown whether Teniposide or its metabolites are excreted in human milk. Given the potential for serious adverse reactions in a nursing infant, breastfeeding is not recommended during therapy.

Male Fertility: Preclinical studies indicate that Teniposide can impair male fertility by causing a decrease in sperm count, genetic damage to sperm, and reduced testicular weight. Male patients of reproductive age should be informed of the risk of infertility and counseled on the option of sperm banking prior to initiating therapy.

Part 4: Drug Interactions and Co-administration

The clinical use of Teniposide requires careful management of potential drug-drug interactions, which can be categorized as either pharmacokinetic or pharmacodynamic.

4.1. Pharmacokinetic Interactions

Interactions primarily involve the modulation of CYP3A4 metabolism and P-glycoprotein (P-gp) transport.

• CYP3A4 Interactions:
• Inhibitors: Co-administration with strong inhibitors of CYP3A4 (e.g., ketoconazole, clarithromycin, atazanavir, amprenavir) can decrease the metabolism of Teniposide, leading to increased plasma concentrations and a higher risk of toxicity.
• Inducers: Conversely, co-administration with strong inducers of CYP3A4 (e.g., carbamazepine, apalutamide, aminoglutethimide, amobarbital) can accelerate Teniposide metabolism, potentially reducing its plasma concentration and compromising its therapeutic efficacy.
• P-glycoprotein (P-gp) Interactions: As Teniposide is a substrate for the P-gp efflux pump, its transport can be affected by P-gp modulators.
• Inhibitors: Drugs that inhibit P-gp (e.g., cyclosporine, clarithromycin, amiodarone) can increase Teniposide's intracellular accumulation and systemic exposure, thereby enhancing both its efficacy and toxicity.

4.2. Pharmacodynamic Interactions

These interactions involve additive or synergistic effects on physiological systems.

• Increased Bleeding Risk: Due to Teniposide-induced thrombocytopenia, concurrent use of anticoagulants (e.g., acenocoumarol), antiplatelet agents (e.g., abciximab, aspirin, NSAIDs), or thrombolytic agents (e.g., alteplase) can significantly increase the risk of serious bleeding events.
• Enhanced Myelosuppression: The risk of severe bone marrow suppression is amplified when Teniposide is combined with other myelosuppressive agents, including other chemotherapies (e.g., altretamine, azacitidine) and certain immunosuppressants (e.g., belatacept).
• Live Vaccines: Administration of live or live-attenuated vaccines is contraindicated in patients receiving Teniposide due to profound immunosuppression, which can lead to uncontrolled viral replication and disseminated infection.

Table 3: Clinically Significant Drug-Drug Interactions with Teniposide

Interacting Agent/Class	Mechanism	Clinical Consequence	Management Recommendation
Strong CYP3A4 Inhibitors (e.g., ketoconazole, clarithromycin)	Pharmacokinetic (Inhibition of metabolism)	Increased Teniposide concentration and toxicity	Avoid or Use Alternate Drug; Monitor closely for toxicity if co-administration is unavoidable
Strong CYP3A4 Inducers (e.g., carbamazepine, apalutamide)	Pharmacokinetic (Induction of metabolism)	Decreased Teniposide concentration and efficacy	Avoid or Use Alternate Drug; Monitor for lack of efficacy
P-gp Inhibitors (e.g., cyclosporine, amiodarone)	Pharmacokinetic (Inhibition of efflux)	Increased Teniposide exposure and toxicity	Use Caution/Monitor
Anticoagulants / Antiplatelets (e.g., warfarin, abciximab, NSAIDs)	Pharmacodynamic (Additive effect)	Increased risk of severe bleeding	Monitor platelet counts and signs of bleeding; Avoid NSAIDs
Other Myelosuppressive Agents	Pharmacodynamic (Additive effect)	Increased severity and duration of bone marrow suppression	Monitor blood counts frequently; Dose adjustments may be necessary
Live Virus Vaccines (e.g., MMR, Varicella, Yellow Fever)	Pharmacodynamic (Impaired immune response)	Risk of disseminated, life-threatening infection	Contraindicated during and for at least 3 months after therapy

Part 5: Historical, Regulatory, and Future Perspectives

5.1. Developmental History

The story of Teniposide begins not in a modern laboratory, but with the historical use of podophyllin, a resin derived from the Podophyllum plant, in folk medicine for centuries. The highly potent but toxic active ingredient, podophyllotoxin, was isolated in the 19th century. Recognizing its antimitotic properties, researchers in the mid-20th century sought to create derivatives with a better therapeutic window. This work, conducted at Sandoz in the 1960s, led to the synthesis of two key epipodophyllotoxins: Teniposide (VM-26) and its analogue, etoposide (VP-16).

Based on impressive preclinical activity against murine leukemias, Teniposide was advanced into clinical trials in 1971. While early results were encouraging, particularly in refractory leukemias, the focus of clinical development soon shifted almost exclusively to etoposide. This pivot was driven in part by perceived advantages in etoposide's formulation, including the availability of an oral dosage form, which simplified administration. Consequently, for many years, Teniposide was considered an under-investigated agent, prompting calls in the late 1980s and early 1990s for its re-evaluation in lymphomas, leukemias, and small cell lung cancer, where it had shown initial promise.

5.2. Global Regulatory Status and Commercial Landscape

The regulatory and market status of Teniposide is fragmented globally, reflecting its evolution as a legacy chemotherapeutic agent in an era of rapidly advancing oncology care.

• United States: Teniposide (Vumon®) received FDA approval in 1992. However, the product has since been discontinued by the manufacturer and is no longer commercially available in the U.S.. The specific reasons for this withdrawal are not publicly detailed but likely reflect a confluence of factors.
• Europe: The drug is approved in several European countries under trade names including Vumon® and Vehem®. Its approval appears to have been granted through national procedures within individual member states rather than a centralized European Medicines Agency (EMA) process. Notably, its approved indications in Europe are broader than in the U.S., covering a range of pediatric solid and hematologic tumors.
• Australia: Vumon® was previously registered with the Therapeutic Goods Administration (TGA) but was cancelled from the Australian Register of Therapeutic Goods (ARTG) on June 22, 2017, at the request of the sponsor, Bristol-Myers Squibb.

This pattern of divergent regulatory fates illustrates the typical lifecycle of an older cytotoxic drug. Teniposide was developed when its significant toxicities were deemed acceptable for treating life-threatening pediatric cancers for which few alternatives existed. As the therapeutic landscape evolved with the introduction of newer, more targeted, and potentially safer agents (e.g., immunotherapies like blinatumomab for ALL), the clinical niche for Teniposide narrowed in markets like the U.S. and Australia. This likely rendered its continued marketing commercially unviable, leading to its withdrawal. In contrast, its broader indication profile or different healthcare economic models in parts of Europe may have sustained its availability for specific, highly refractory conditions where it still holds clinical value.

5.3. Current Research and Future Directions

Despite its discontinuation in some major markets, Teniposide remains a subject of clinical investigation, suggesting its unique mechanism of action is still considered relevant. Current research is focused on repositioning this older drug within modern therapeutic paradigms, particularly in biomarker-selected populations and in novel combination regimens.

• Small Cell Lung Cancer (SCLC): A Phase 2 clinical trial (NCT06758700) is currently evaluating Teniposide as a later-line therapy for patients with extensive-stage SCLC whose tumors have high expression of the c-Myc oncogene. This represents a sophisticated, biomarker-driven approach to identify a patient subpopulation that may derive particular benefit from a topoisomerase II inhibitor.
• Primary Central Nervous System Lymphoma (PCNSL): A new study (NCT07074470) is exploring a novel combination of Teniposide with a PD-1 monoclonal antibody (an immune checkpoint inhibitor) and selinexor (a nuclear export inhibitor) for patients with relapsed or refractory PCNSL. This trial aims to leverage potential synergies between cytotoxic chemotherapy, immunotherapy, and targeted agents.
• Historical Context in Lymphoma: Its role in lymphoma has been a long-standing area of interest, with earlier trials like NCT00004916 investigating its use in combination with ifosfamide and paclitaxel for relapsed non-Hodgkin's lymphoma.

The future clinical role of Teniposide is unlikely to be as a broad-spectrum agent. Instead, these ongoing studies suggest a potential for its revitalization as a niche therapeutic. Its future may lie in its application for specific, molecularly defined cancer subtypes or as a component in innovative combinations that pair its potent cytotoxic effects with the mechanisms of modern immunotherapy and targeted drugs.

Conclusions

Teniposide is a potent, cell-cycle specific topoisomerase II inhibitor with established efficacy in refractory pediatric hematologic malignancies. Its development from a natural product, podophyllotoxin, into a semi-synthetic chemotherapeutic agent highlights a classic paradigm in drug discovery. Its pharmacological profile is defined by a paradox: while demonstrating superior in vitro potency and cellular uptake compared to its analogue etoposide, its clinical utility is tempered by unfavorable pharmacokinetics, particularly its extensive plasma protein binding.

The clinical application of Teniposide is characterized by a significant and manageable toxicity profile, dominated by severe myelosuppression and a risk of hypersensitivity reactions. The most concerning long-term risk is the development of therapy-related secondary leukemias, a direct consequence of its DNA-damaging mechanism of action. This risk underscores the critical need for careful patient selection and risk-benefit assessment, especially in pediatric populations with long life expectancies.

The drug's divergent global regulatory status—approved for broad use in Europe but discontinued in the United States and Australia—reflects the dynamic nature of the oncology market, where legacy cytotoxic agents are often supplanted by newer, more targeted therapies. Nonetheless, ongoing clinical trials exploring Teniposide in biomarker-selected populations and in combination with immunotherapy suggest a potential for its repositioning. The future of Teniposide may not be in widespread use but as a valuable tool for specific, hard-to-treat cancers where its potent and unique mechanism of action can still address a critical unmet medical need.

Works cited

1. Teniposide | 29767-20-2 - ChemicalBook, accessed October 17, 2025, https://www.chemicalbook.com/ChemicalProductProperty_EN_CB0455475.htm
2. CAS No. 29767-20-2 | MedChemExpress (MCE) Life Science Reagents, accessed October 17, 2025, https://www.medchemexpress.com/search.html?q=29767-20-2&ft=&fa=&fp=
3. teniposide | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed October 17, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=6843
4. Teniposide: Uses, Interactions, Mechanism of Action | DrugBank ..., accessed October 17, 2025, https://go.drugbank.com/drugs/DB00444
5. VUMON® (teniposide injection) - accessdata.fda.gov, accessed October 17, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020119s010s011lbl.pdf
6. Teniposide | C32H32O13S | CID 452548 - PubChem, accessed October 17, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Teniposide
7. Teniposide - Wikipedia, accessed October 17, 2025, https://en.wikipedia.org/wiki/Teniposide
8. Definition of teniposide - NCI Drug Dictionary, accessed October 17, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/teniposide
9. Teniposide injection - Cleveland Clinic, accessed October 17, 2025, https://my.clevelandclinic.org/health/drugs/20307-teniposide-injection
10. Teniposide | Topoisomerase inhibitor | Mechanism | Concentration - Selleck Chemicals, accessed October 17, 2025, https://www.selleckchem.com/products/Teniposide(Vumon).html
11. Teniposide (NSC 122819, VM-26, CAS Number: 29767-20-2) | Cayman Chemical, accessed October 17, 2025, https://www.caymanchem.com/product/14425/teniposide
12. Teniposide | DNA Topoisomerases - Tocris Bioscience, accessed October 17, 2025, https://www.tocris.com/products/teniposide_6975
13. Etoposide: History and mechanism of action - LGC Standards, accessed October 17, 2025, https://www.lgcstandards.com/ES/en/Resources/Articles/Pharma-roots-Etoposide
14. Teniposide Injection - accessdata.fda.gov, accessed October 17, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/020119s013lbl.pdf
15. Mechanisms of action of teniposide (VM-26) and comparison with ..., accessed October 17, 2025, https://pubmed.ncbi.nlm.nih.gov/1329225/
16. Teniposide | CancerQuest, accessed October 17, 2025, https://cancerquest.org/node/6455
17. The clinical pharmacology of etoposide and teniposide - PubMed, accessed October 17, 2025, https://pubmed.ncbi.nlm.nih.gov/3297462/
18. Etoposide and Teniposide, accessed October 17, 2025, https://resolve.cambridge.org/core/services/aop-cambridge-core/content/view/D6CE25846134A4AD83B1C67977339094/9780511983665c4_p113-137_CBO.pdf/etoposide_and_teniposide.pdf
19. Teniposide in adult solid tumors: a historical perspective - PubMed, accessed October 17, 2025, https://pubmed.ncbi.nlm.nih.gov/1411638/
20. TENIPOSIDE 1. Exposure Data - IARC Publications, accessed October 17, 2025, https://publications.iarc.who.int/_publications/media/download/2513/3c0cc91f441c75e15d08a1239d956bb560e9aca8.pdf
21. vm 26, Vumon (teniposide) dosing, indications, interactions, adverse effects, and more, accessed October 17, 2025, https://reference.medscape.com/drug/vm-26-vumon-teniposide-342248
22. Teniposide - DRUG NAME - BC Cancer, accessed October 17, 2025, http://www.bccancer.bc.ca/drug-database-site/Drug%20Index/Teniposide_monograph_1July2014.pdf
23. Teniposide - Vumon® - GlobalRPH, accessed October 17, 2025, https://globalrph.com/oncology/teniposide-vumon/
24. Teniposide (Vumon®, VM-26) | OncoLink, accessed October 17, 2025, https://www.oncolink.org/cancer-treatment/oncolink-rx/teniposide-vumon-R-vm-26
25. Teniposide (intravenous route) - Side effects & uses - Mayo Clinic, accessed October 17, 2025, https://www.mayoclinic.org/drugs-supplements/teniposide-intravenous-route/description/drg-20066257
26. Investigation of the additive potential of teniposide and vincristine in non-Hodgkin's lymphoma. Australian and New Zealand Lymphoma Group - PubMed, accessed October 17, 2025, https://pubmed.ncbi.nlm.nih.gov/2873890
27. Vumon Factsheet, Uses & Common Side Effects - Rexall, accessed October 17, 2025, https://www.rexall.ca/article/drug/view/id/1406
28. Teniposide | Davis's Drug Guide for Rehabilitation Professionals, accessed October 17, 2025, https://fadavispt.mhmedical.com/content.aspx?bookid=1873§ionid=139027350
29. Teniposide - Together by St. Jude™, accessed October 17, 2025, https://together.stjude.org/en-us/treatment-tests-procedures/medicines-list/teniposide.html
30. Vumon (teniposide): Drug Basics and Frequently Asked Questions - GoodRx, accessed October 17, 2025, https://www.goodrx.com/vumon/what-is
31. Etoposide: four decades of development of a topoisomerase II inhibitor - PubMed, accessed October 17, 2025, https://pubmed.ncbi.nlm.nih.gov/9893622/
32. Teniposide in the treatment of leukemia: a case study of conflicting ..., accessed October 17, 2025, https://ascopubs.org/doi/10.1200/JCO.1988.6.2.351
33. teniposide | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed October 17, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?tab=clinical&ligandId=6843
34. European Medicines Agency (EMA), accessed October 17, 2025, https://www.ema.europa.eu/en/medicines
35. National registers of authorised medicines | European Medicines Agency (EMA), accessed October 17, 2025, https://www.ema.europa.eu/en/medicines/national-registers-authorised-medicines
36. VUMON teniposide 50mg/5mL injection ampoule Cancelled under s30(1)(c), accessed October 17, 2025, https://www.tga.gov.au/resources/cancellations-by-sponsors/vumon-teniposide-50mg5ml-injection-ampoule-cancelled-under-s301c
37. Australian Register of Therapeutic Goods (ARTG), accessed October 17, 2025, https://www.tga.gov.au/products/australian-register-therapeutic-goods-artg
38. Extensive Stage Small Cell Lung Cancer Not Yet Recruiting Phase 2 Trials for Teniposide (DB00444) - DrugBank, accessed October 17, 2025, https://go.drugbank.com/indications/DBCOND0029404/clinical_trials/DB00444?phase=2&status=not_yet_recruiting
39. Study Details | NCT06758700 | Post-line Treatment with Teniposide ..., accessed October 17, 2025, https://www.clinicaltrials.gov/study/NCT06758700
40. Study Details | NCT07074470 | Combination Regimen of Teniposide, PD-1 Monoclonal Antibody and Selinixor for Patients With Relapsed or Refractory PCNSL | ClinicalTrials.gov, accessed October 17, 2025, https://clinicaltrials.gov/study/NCT07074470
41. Study Details | NCT00004916 | Ifosfamide, Teniposide, and Paclitaxel in Treating Patients With Relapsed Non-Hodgkin's Lymphoma | ClinicalTrials.gov, accessed October 17, 2025, https://clinicaltrials.gov/study/NCT00004916